77 results about "Cancer Early Diagnosis" patented technology

The invention discloses a non-small cell lung cancer targeted therapy gene detection method, and belongs to the field of gene detection. The method for detecting 466 mutations of 12 oncogenes is developed by multiplex PCR and high throughput sequencing technologies, wherein the oncogenes are AKT1, ALK, BRAF, EGFR, ERBB4, FGFR1, FGFR2, FGFR3 , KRAS, MET, PIK3CA, and PTEN, and the mutations may be substitutions, insertions and / or deletions of one or more bases. The detection method provided by the invention has the advantages of high detection sensitivity of up to 0.01%, and clear and objective detection results, can be directly used for reflecting specific mutation sites of the relevant gene, directly used for guiding clinical non-small cell lung cancer targeted dosage, and used for early diagnosis or auxiliary diagnosis and screening of cancers as well as post-cancer surveillance.

The invention discloses a primer, a kit and a method for determining a lung cancer gene mutation site based on a high-flux sequencing technology, which belongs to the field of biological molecular detection. The invention discloses a method and a kit for determining a lung cancer gene mutation site based on a high-flux sequencing technology. The method comprises the following steps: extracting tumor tissue DNA; designing a panel of a lung cancer targeting treatment molecular diagnosis associated gene; performing the PCR primer amplification; and establishing a library, and performing the high-flux sequencing. The specific primer and the kit for determining the lung cancer gene mutation site are used for detecting 316 mutation situations of 16 oncogenes, and the mutation can be the replacement, insertion and/or deletion of one or more alkaline groups. The sensitivity of the detection method and the kit of the invention can reach up to 1 percent, the detection result is definite and objective and can directly reflect the specific mutation site of the reaction associated gene and has important significance for early diagnosis or auxiliary diagnosis and screening of the cancer and theprognosis monitoring of the cancer.

A nanopartide and its avidin probe are disclosed. Said gene probe for detecting the mutation or non-mutation of DNA is prepared from nanoparticles or colloidal particles and avidin, streptavidin, or antibiotin through preparing colloidal gold and preparing the compound. Its advantges are high sensitivity, specificity and speed.

The invention discloses a method for detecting an exosome GPC1 protein. The method comprises 1, taking a sample to be detected, 2, adding exosome specific antibody-modified immunomagnetic beads into the sample to be detected, 3, orderly adding a biotin-labeled anti-GPC1 antibody, a streptavidin-labeled horse radish peroxidase and a horse radish peroxidase substrate into the immunomagnetic beads and 4, carrying out detection through a magnetic-electrochemical sensor device. The method has advantages of an immunomagnetic bead technology and an electrochemical sensor detection technology and has high sensitivity and a small sample amount. The detection device has a low cost, a small volume and high flux, specifically detects a specific exosome for GPC1 protein expression and has an important meaning for cancer early stage diagnosis and treatment detection.

The invention discloses a multiple PCR primer group for detecting a gene related to colorectal cancer administration. The primer group comprises an upstream primer group and a downstream primer group, wherein the 5' end sequence of the upstream is complementary to partial sequence of a to-be-detected primer, and the 3' end of the upstream primer is a specific sequence combined to a target zone; the 5' end sequence of the downstream primer is complementary with partial sequence of the to-be-detected primer, and the 3' end of the downstream primer is a specific sequence combined to the target zone, and the sequence of the middle position of the downstream primer is a molecule tag sequence. The invention further discloses a kit containing the multiple PCR primer group and a method for detecting the gene related to colorectal cancer administration, which can be used for simultaneously detecting exon regions of 8 genes related to target medicines for treating colorectal cancer and mutation of 23 polymorphic sites related to chemotherapeutic drugs, can be directly used for assisting clinical colorectal cancer administration, and can be used in cancer early diagnosis, auxiliary diagnosis and screening or cancer prognosis monitoring.

The invention belongs to the field of biotechnology and medical technology and provides a miRNA marker related to malignant transformation of colitis and proctitis. The marker is a composition of miR-138-5p, miR-145-5p, miR-146a-5p and miR-150-5p. The invention further provides a primer of the miRNA marker, application of the miRNA marker in preparation of a rectal cancer early-diagnosis kit, and the rectal cancer early-diagnosis kit. The provided miRNA marker, including miR-138-5p, miR-145-5p, miR-146a-5p and miR-150-5p and related to malignant transformation of colitis and proctitis is used for early screening of the colon cancer and the rectal cancer and has the characteristics of easiness in operation, high specificity and high sensitivity.

The invention relates to a method for cancer diagnosis and/or cancer risk hazard degree assessment in subjects. The method comprises the following steps: a) determining DNA methylation states of samples from the subjects and samples from a healthy control group on at least one DNA methylation site; b) comparing the DNA methylation states of the samples from the subjects at the DNA methylation site with the DNA methylation states of the samples from the healthy control group at the corresponding DNA methylation site; and if the methylation states of the samples from the subjects and the samples from the healthy control group have remarkable difference, showing that the subjects have cancers or have cancer risks. The invention further provides a kit for the method provided by the invention.

The invention discloses a magnetic resonance contrast agent constructed by amphipathic polysaccharide-wrapped super-paramagnetic nanoparticles and a preparation method thereof, and the magnetic resonance contrast agent is characterized in that amphipathic polysaccharides take glucosans as main chain grafted hydrophobic chain segment molecules (such as fatty acids), self-assembly is performed in aselective solvent for forming micelles, and hydrophobic super-paramagnetic nanoparticles (such as ferroferric oxide nano-crystals) can be loaded so as to get a water-soluble nano compound. The nano compound has good biological compatibility, and the loaded nanoparticles can keep the original advantages of physical properties. The nano-compound can be used as the magnetic resonance contrast agent,thereby having extensive application prospects in magnetic resonance enhanced imaging, early diagnosis of cancers, image tracking efficacy evaluation and other biomedical fields.

The invention provides an automatic detection system of circulating tumor cells based on a Raman spectrum. The system is composed of a blood sample processing module, a circulating tumor cell detection module, a data processing module and a result output module, wherein the blood sample processing module is mainly based on an enriching effect on circulating tumor cells of a microporous filter chip, the circulating tumor cell detection includes optical microimaging detection and micro-Raman spectrum detection, and detection data are compared with a database, so that information such as the quantity, kind, period and the like of the circulating tumor cells (CTC) are obtained ultimately.The system has the advantages of high integration level, simplicity in operation and good specificity of the Raman spectrum, a detection result can be obtained when a blood sample is directly put in the system, and the system can be widely applied to the fields of clinical blood test, early diagnosis and prognosis monitoring of cancer, basic scientific research and the like.

The invention discloses a preparation method of a kidney-removing ultra-small double-targeted bimodal magnetic resonance contrast agent and belongs to the technical field of nano materials and bioengineering. The method comprises the following step: by adopting an improved co-precipitating method, preparing succinyl ultralow molecular weight heparin coated water soluble ultra-small ferroferric oxide nanoparticles under the nitrogen protection, wherein the average grain size of the obtained nanoparticle nucleus is 2 nm, and the thickness of a polymer coating is 1.0-2 nm. A lot of carboxyl on succinyl ultralow molecular weight heparin not only can enable ferric oxide nanoparticles to be dispersed in deionized water stably, but also can be combined with targeted molecules, so that the material is endowed with magnetic property and folic acid double targeted function. The synthesized magnetic and folic acid double targeted compound magnetic nanoparticles are uniform in shape, high in dispersibility, high in biocompatibility, high in T1 relaxation rate and short in half life in blood of a mouse body, and is substantially and fully removed out of the body within 48 hours. Precise targeted tumor T1 and T2 magnetic resonance imaging is achieved without affecting the normal physiological activity of the mouse. As the magnetic resonance contrast agent, the ultra-small double-targeted bimodal magnetic nanoparticles prepared by the method have a wide application prospect in the biomedical fields of magnetic resonance imaging, early diagnosis of cancers, image tracking therapeutic effect evaluation and the like.

The invention belongs to the field of nano-biomedicine. The traditional early cancer diagnosis has the defects of low sensitivity, high cost, inconvenient use, and the like. The surface enhanced Raman scattering technology of gold nanorods can realize the sensitivity of single molecule detection. In the invention, by using the strong absorption characteristic of cancer cells for the gold nanorods, the gold nanorods are collected in a tumor tissue through intravenous injection, Raman probe molecules are attached to the surfaces of the gold nanorods, and the early-period and high-sensitivity detection of cancers is realized by measuring a Raman spectrum of the Raman probe molecules. Absorption peaks of the selected gold nanorods are in a near-infrared wave band, thereby pump light and scattered light can be easy to enter and perforate a human body. The invention provides a novel, efficient and convenient method for the clinical diagnosis of early cancers.

The invention belongs to the field of molecular imaging probes and particularly relates to a preparation method of a dual-modal nano imaging drug Dex-Rho-99mTc based on glucan, and an application of the drug in imaging diagnosis. The general formula of the drug is Rho-Dex-PEG-DTPA-99mTc, wherein the Dex represents for the glucan of which the molecular weight is 10-100k, the PEG represents for polyethylene glycol of which the molecular weight is 1-10k, the Rho represents for a fluorescent group rhodamine, the DTPA is a chelating agent of an imaging nuclide and the 99mTc is a radioisotope Technetium-99 used for SPECT imaging. In the invention, the surface of the high-molecular material glucan is modified by a certain number of amino groups and the PEG, the fluorescent group and the SPECT imaging groups are connected to the glucan supporter through the amino groups and finally the drug is marked by the radioisotope [99mTc]. The drug is good in biocompatibility, is simple in the preparation method, is safe and convenient to use and can be employed in dual-modal imaging. The dual-modal nano imaging drug has wide application prospects in the biomedical fields of early diagnosis of cancer, medicine delivery under guide of imaging, noninvasive iconography curative effect evaluation and the like.

The invention relates to a bismuth sulfide-zinc protoporphyrin composite material with a tumor photodynamic therapy (PDT) property under excitation of near-infrared light as well as a preparation method and application and belongs to the field of composite materials, aiming at solving the problem that the PDT efficiency is relatively low, caused by photoelectron-hole compounding in a photodynamictherapy process of bismuth sulfide and an anti-oxidization stress capability of heme oxygenase (HO-1) in cells. The composite material is the bismuth sulfide-zinc protoporphyrin composite material which is obtained by synthesizing a polyN-isopropylacrylamide-acrylamide copolymer modified bismuth sulfide nano-material and then carrying out condensation reaction of carboxyl and amino. The prepared composite material has the effect of enhancing the photodynamic therapy efficiency through two ways of inhibiting the activity of the heme oxygenase and promoting electron-hole separation; meanwhile, the material provided by the invention has good biocompatibility, light stability, CT (Computed Tomography) imaging capability and enhanced PDT efficiency; a thought is provided for designing a novel nano diagnosis and treatment integrated system and the material has important meaning on early-stage diagnosis and treatment of cancers.

The invention discloses a nano artificial antibody inhibitor used for the real-time imaging of tumor markers in living cells, and a preparation method thereof. The inhibitor is to construct a molecularly imprinted polymer artificial antibody having biomimetic molecular recognition performance on a tumor marker on the surface of a nanomaterial, has the advantages of being high in specificity, goodin repeatability and good in physical and chemical stability, and has temperature or pH environment response performance; through the utilization of the surface plasma resonance effect of nano-gold orthe fluorescence effect of quantum dots, Raman spectroscopy quantitative detection or fluorescence quantitative detection of the tumor marker can be realized, and the inhibitor has the advantages ofbeing rapid, high in sensitivity, marking-free and nondestructive and can perform quantitative detection in real time; and the inhibitor can realize the real-time visualization imaging of the tumor marker in living cells after being introduced into the cells, and through the selective capturing and enrichment on associated proteins which can regulate the growth of tumor, the inhibitor has effectsof inhibiting the growth of the tumor and can be used for early diagnosis and targeted therapy of cancer.

The invention discloses a device (instrument) which has a pre-sharpening processing unit and can automatically perform early diagnosis and treatment effect inspection on cancer. The centrifuge, diluter and computer are integrated. The device can directly detect the characteristic fluorescence spectrum and changing rules of the blood of cancer patients, and realize the early diagnosis and treatment effect inspection of various cancers; The difference between the half-peak width value of the 515nm main peak and the ratio I515nm/I624nm of its intensity to the 624nm fluorescence characteristic peak is used to more accurately distinguish and detect various types of cancer. The advantages of this early diagnosis and treatment effect inspection device are its clear principle, solid foundation, simple equipment for in vitro detection, convenient operation, high detection accuracy, fast speed and low cost; To trauma and pain, easy to use widely, simple to make detection samples.

The invention provides a protective agent, a preservation method and application of a low-concentration DNA reference material. The protective agent comprises salmon sperm DNA. A sequence of a TP53 gene with the length of 300 bp is selected as a target fragment to develop a DNA reference material with a low-concentration level, the salmon sperm DNA with the concentration of 20 [mu]g/mL to 100 [mu]g/mL is taken as a protective agent for protecting, a the DNA reference material is stored in a low-absorption centrifuge pipe and placed in a freezing condition of -15 DEG C to -20 DEG C, and the concentration stability of the DNA reference material is maintained within 6 months; the DNA reference material has good uniformity and stability, the accurate reliability of a biological frontier detection technology are ensured, the detection ability of clinical detection and early diagnosis of cancer is improved, and the reliable measurement support is provided for precision medical plans.